NCT06323044Recruiting
MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 14 Mar 2024
- Start date
- 11 Feb 2025
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Roswell Park Cancer Institute
- NCT number
- NCT06323044
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 11 Feb 2025 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Parent is unwilling or unable to follow protocol requirements.
Who the study is looking for
- Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)
- Child patient age 365 days to \< 19 years at time of study entry.
- Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.
- Verbal fluency in English, or Spanish
- Parent has a smartphone or computer access with an Internet connection.
- Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Roswell Park Cancer Institute Coordinator of this site? Confirm its status | Buffalo | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.